Moreover, The PARADIGM-HF and DAPA-HF trials; on the other hand, have neprilysin inhibition (sacubitril/valsartan) and SGLT2 inhibition (Dapagliflozin), respectively [27, 28]. The gene discussed is MME; the disease is hydrops fetalis.